Dipna Pharmachem Ltd
Incorporated in 2011, Dipna Pharmachem Ltd
is in the business of Pharmaceutical Trading[1]
- Market Cap ₹ 36.0 Cr.
- Current Price ₹ 15.0
- High / Low ₹ 15.2 / 6.40
- Stock P/E 43.3
- Book Value ₹ 15.8
- Dividend Yield 0.00 %
- ROCE 7.05 %
- ROE 3.52 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.95 times its book value
- Debtor days have improved from 103 to 68.7 days.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Promoter holding is low: 9.98%
- Company has a low return on equity of 7.02% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|
17 | 20 | 30 | 31 | 73 | 100 | 164 | 181 | |
16 | 20 | 30 | 31 | 71 | 98 | 161 | 178 | |
Operating Profit | 0 | 0 | 0 | 0 | 2 | 2 | 3 | 3 |
OPM % | 2% | 2% | 1% | 1% | 3% | 2% | 2% | 2% |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Interest | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 |
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit before tax | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 1 |
Tax % | 14% | 40% | 0% | 60% | 26% | 34% | 24% | |
0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | |
EPS in Rs | 6.00 | 3.00 | 6.00 | 2.00 | 117.00 | 0.37 | 0.45 | 0.34 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 52% |
3 Years: | 74% |
TTM: | 22% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 105% |
3 Years: | 279% |
TTM: | -30% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | 69% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 7% |
3 Years: | 7% |
Last Year: | 4% |
Balance Sheet
Figures in Rs. Crores
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|
Equity Capital | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 12 | 24 | 24 |
Reserves | 0 | 0 | 1 | 1 | 2 | 12 | 13 | 14 |
5 | 6 | 10 | 12 | 10 | 16 | 19 | 17 | |
6 | 8 | 8 | 12 | 24 | 37 | 76 | 78 | |
Total Liabilities | 11 | 14 | 18 | 25 | 36 | 78 | 133 | 133 |
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
11 | 14 | 18 | 25 | 36 | 78 | 133 | 133 | |
Total Assets | 11 | 14 | 18 | 25 | 36 | 78 | 133 | 133 |
Cash Flows
Figures in Rs. Crores
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|
-3 | -2 | 3 | -21 | -5 | |||
0 | 0 | -0 | -0 | -0 | |||
3 | 2 | -3 | 26 | 14 | |||
Net Cash Flow | 0 | 0 | -0 | 5 | 8 |
Ratios
Figures in Rs. Crores
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|
Debtor Days | 132 | 160 | 134 | 176 | 135 | 104 | 69 |
Inventory Days | 112 | 66 | 70 | 89 | 34 | 72 | 86 |
Days Payable | 142 | 148 | 105 | 145 | 123 | 139 | 172 |
Cash Conversion Cycle | 103 | 78 | 99 | 120 | 46 | 38 | -17 |
Working Capital Days | 116 | 114 | 119 | 150 | 59 | 126 | 96 |
ROCE % | 8% | 5% | 3% | 17% | 9% | 7% |
Documents
Announcements
-
Clarification Sought On Significant Movement In Price
30 Dec - Clarification on price movement; no sensitive info.
-
Clarification sought from Dipna Pharmachem Ltd
30 Dec - Exchange has sought clarification from Dipna Pharmachem Ltd on December 30, 2024, with reference to Movement in Price.
- Results-Delay in Financial Results 18 Dec
-
Results-Delay in Financial Results
11 Dec - Submission of unaudited financial results for H1 2024.
-
Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. 11Th December, 2024
11 Dec - Board approved unaudited financial results for H1 2024.
Business Overview:[1]
DPL is a trader, importer, and exporter of industrial Chemical and Pharmaceutical Raw materials, APIs, Solvents, Excipients, Intermediates, and Formulations. It provides assistance in setting up contract manufacturing compliance for regulated, semi-regulated pharmaceutical companies with all the global benchmark parameters of certificates like WHO-GMP